Oncolytics Biotech Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCY research report →
About the company
Oncolytics Biotech Inc. , a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
- CEO
- Jared Kelly
- IPO
- 2001
- Employees
- 29
- HQ
- Calgary, AB, CA
Price Chart
- Market Cap
- $90.23M
- P/E
- -3.79
- P/S
- 0.00
- P/B
- -27.95
- EV/EBITDA
- -3.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 5214.36%
- ROIC
- -1221.77%
- Revenue
- $0 · 0.00%
- Net Income
- $-39,461,086 · -24.44%
- EPS
- $-0.41 · 0.00%
- Op Income
- $-39,414,434
- FCF YoY
- -1.44%
- 52W High
- $1.51
- 52W Low
- $0.77
- 50D MA
- $0.90
- 200D MA
- $1.02
- Beta
- 1.09
- Avg Volume
- 1.31M
Get TickerSpark's AI analysis on ONCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | McAdory John Bearden | other | 500,000 |
| Jun 1, 26 | Glover Stephen C. | other | 0 |
| Mar 11, 26 | Parsons James T. | buy | 10,000 |
| Mar 12, 26 | Kelly Jared | buy | 5,050 |
| Feb 12, 26 | Kelly Jared | buy | 29,500 |
| Feb 11, 26 | Kelly Jared | buy | 5,600 |
| Feb 12, 26 | Look Kirk | buy | 12,000 |
| Feb 12, 26 | Pisano Wayne | buy | 30,000 |
| Feb 12, 26 | Heineman Thomas Charles | buy | 12,132 |
| Feb 12, 26 | Brown Deborah Margaret | buy | 25,000 |
Our ONCY coverage
Recent articles, reports, and earnings notes.
No research on ONCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONCY report →Similar companies
Peers in the same neighborhood.